New data for tolebrutinib, Sanofi’s investigational brain-penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression
from Sanofi - Aventis Groupe https://ift.tt/wrvamRM
via IFTTT
Media Update: New data for tolebrutinib, Sanofi’s investigational brain-penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression
https://ift.tt/U2aApDw
from Sanofi - Aventis Groupe https://ift.tt/wrvamRM
via IFTTT
from Sanofi - Aventis Groupe https://ift.tt/wrvamRM
via IFTTT
0 Comments
Please ,
Do not enter any kind of span link